• 1
    Fox RI. Sjögren’s syndrome. Lancet 2005;366:32131.
  • 2
    Konttinen YT, Käsna-Ronkainen L. Sjögren’s syndrome: viewpoint on pathogenesis. Scand J Rheumatol 2002;116(31 Suppl):1522.
  • 3
    Delaleu N, Jonsson MV, Appel S, Jonsson R. New concepts in the pathogenesis of Sjögren’s syndrome. Rheum Dis Clin N Am 2008;34:83345.
  • 4
    Nikolov NP, Illei GG. Pathogenesis of Sjögren’s syndrome. Curr Opin Rheumatol 2009;21:46570.
  • 5
    Lazarus MN, Robinson D, Mak V, Møller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren’s syndrome. Rheumatology 2006;45:10125.
  • 6
    Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 2002;46:7417.
  • 7
    Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 2004;50:12629.
  • 8
    Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch Intern Med 2004;164:127584.
  • 9
    Bowman SJ. Patient-reported outcomes including fatigue in primary Sjögren’s syndrome. Rheum Dis Clin N Am 2008;34:94962.
  • 10
    Vitali C. Measurement of disease activity and damage in Sjögren’s syndrome. Rheum Dis N Am 2008;34:96371.
  • 11
    Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M et al. Sjögren’s Syndrome Disease Damage Index and Disease Activity Index. Arthritis Rheum 2007;56:222331.
  • 12
    Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E et al. Sjögren’s Systemic Clinical Activity Index (SCAI) – a systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. Rheumatology (Oxford) 2007;46:184551.
  • 13
    Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E et al. EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease index in primary Sjögren’s syndrome. Ann Rheum Dis 2009; doi:10.1136/ard.2009.110619 [Epub ahead of print].
  • 14
    Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M et al. The Sjögren’s Syndrome Damage Index – a damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome. Rheumatology (Oxford) 2008;47:11938.
  • 15
    Bowman SJ, Booth DA, Platts RG, UK Sjögren’s Interest Group. Measurement of fatigue and discomfort in primary Sjögren’s syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004;43:75864.
  • 16
    Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000;29:208.
  • 17
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:5548.
  • 18
    Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas AG, Theander E et al. Development and preliminary validation of the EULAR Sjögren’s syndrome disease activity index (ESSDAI): a new consensual disease activity index that detects changes accurately. Presented at the American College Rheumatology 2009 Annual Meeting, Pennsylvania, October 18.
  • 19
    Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009;48:6915.
  • 20
    Segal B, Bowman SJ, Fox PC, Vivino FB, Murukutla N, Brodscholl J et al. Primary Sjögren’s Syndrome: health experiences and predictors of health quality among patients in the United States. Health and Quality of Life Outcomes 2009;7:46. doi:10.1186/1477-7525-7-46.
  • 21
    Bowman SJ, Hamburger J, Richards A, Barry RJ, Rauz S. Patient-reported outcomes in primary Sjögren’s syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort-Sicca Symptoms Inventory. Rheumatology (Oxford) 2009;48:1403.
  • 22
    Bowman SJ, Booth DA, Platts RG, Field A, Rostron J, UK Sjögren’s Interest Group. Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren syndrome. J Rheumatol 2003;30:125966.
  • 23
    Sutcliffe N, Stoll T, Pyke S, Isenberg DA. Functional disability and end organ damage in patients with Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SS), and primary SS. J Rheumatol 1999;26:5047.
  • 24
    Bowman SJ. Collaborative research into outcome measures in Sjögren’s syndrome. Update on disease assessment. Scand J Rheumatol 2002;116(31 Suppl):237.
  • 25
    Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ. Weak association between subjective symptoms and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis 1998;57:204.
  • 26
    Pijpe J, Van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum 2005;52:274050.
  • 27
    Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:3107.
  • 28
    Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N et al. Effective rituximab treatment in primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:9608.
  • 29
    Barendregt PJ, Visser MR, Smets EM, Tulen JH, Van Den Meiracker AH, Boomsma F et al. Fatigue in primary Sjögren’s syndrome. Ann Rheum Dis 1998;57:2915.
  • 30
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J et al. Reduction of fatigue in Sjögren’s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008;67:15414.
  • 31
    Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:34754.
  • 32
    Mariette X. Therapeutic potential for B-cell modulation in Sjögren’s syndrome. Rheum Dis Clin N Am 2008;34:102533.
  • 33
    Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren’s syndrome. Scand J Immunol 2008;68:55464.
  • 34
    Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren’s syndrome. J Rheumatol 2003;30:240612.
  • 35
    Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases. Arch Intern Med 2005;165:233744.
  • 36
    Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution and morbidity and mortality pf primary Sjögren’s syndrome. Semin Arthritis Rheum 2000;29:296304.
  • 37
    Brito-Zerón P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:135962.
  • 38
    Ramos-Casals M, Brito-Zerón P, Yagüe J, Akasbi M, Bautista R, Ruano M et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren’s syndrome. Rheumatology (Oxford) 2005;44:8994.
  • 39
    Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796803.
  • 40
    Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in patients with primary Sjögren’s syndrome. Arthritis Rheum 1996;39:76772.
  • 41
    Talal N, Sokoloff L, Barth WF. Extrasalivary lymphoid abnormalities in Sjögren’s syndrome (reticulum-cell sarcoma, “pseudolymphoma”, macroglobulinemia). Am J Med 1967;43:5065.
  • 42
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, Members of the European Concerted Action on Sjögren’s Syndrome. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum 1999;42:176572.
  • 43
    Stevens RJ, Hamburger J, Ainsworth JR, Holmes G, Bowman SJ. Flares of systemic disease in primary Sjögren’s syndrome. Rheumatology (Oxford) 2005;44:4023.